Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
about
Rho GTPases: Novel Players in the Regulation of the DNA Damage Response?Flanking Bases Influence the Nature of DNA Distortion by Platinum 1,2-Intrastrand (GG) Cross-LinksLate activation of stress kinases (SAPK/JNK) by genotoxins requires the DNA repair proteins DNA-PKcs and CSBA new isoquinolinium derivative, Cadein1, preferentially induces apoptosis in p53-defective cancer cells with functional mismatch repair via a p38-dependent pathway.Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer modelPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsCellular responses to Cisplatin-induced DNA damage.Cisplatin in cancer therapy: molecular mechanisms of actionOxaliplatin: a review of evolving concepts.MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells.Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage.Molecular mechanisms of resistance and toxicity associated with platinating agents.DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents.DNA damage response in cisplatin-induced nephrotoxicity.In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumorsA Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair DeficienciesCisplatin: a review of toxicities and therapeutic applications.Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy.GADD45α modulates curcumin sensitivity through c-Abl- and JNK-dependent signaling pathways in a mismatch repair-dependent manner.Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses.DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2.The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x.Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells.MLH1-deficient HCT116 colon tumor cells exhibit resistance to the cytostatic and cytotoxic effect of the poly(A) polymerase inhibitor cordycepin (3'-deoxyadenosine) in vitro.
P2860
Q26782005-592D3A5C-503E-4782-9F1A-93EFC9427097Q27671829-029A7717-2208-4DB1-8817-0D83ACC28D31Q28509902-2513DC0C-7F21-4B5F-A8B4-B2981C6CF304Q33516915-1939F596-524E-4384-BE49-9354BC3DE237Q33710082-4643252A-4B83-4C8E-8ADE-1902F89DB36AQ34008793-83ADBA11-0914-40FB-B153-0CDEB98B7E1EQ34089685-7B87A452-6C6F-4B2A-89D3-0EFC42A7332DQ34098163-DBEDD821-A4F8-4D2E-B344-AE72BD419F0EQ34569008-1F80B54F-9D09-4417-AE90-8AA13DDB4573Q34752116-49426CA8-B342-488F-9ECB-738445BDBD9BQ34956579-D1A23E8C-75B6-4317-952F-FD8DD1349C92Q35198447-49AF99DA-60DB-411D-94C2-A727E3444FC1Q35567250-03F2A5BE-9B26-41F8-AF23-F02716779A9FQ35758048-34AC48F2-1EE9-4442-86B4-BE43A87438DCQ35996723-EF8D31B7-0343-4543-A681-A1071570D001Q36525449-D3A16D97-0738-4AC5-AC3D-D9F660C4DFD7Q37275619-3444FC5A-F0A8-4F33-8B1A-E4BA5BAC942AQ37276892-26967373-83BB-42D2-A4D8-41DFD6D74BE5Q37380106-72561023-48BD-4E42-AEF2-C8BBA40003A8Q37536696-A6E8F850-208F-4BD7-9A5E-AB88387A758AQ38641139-8CCE06ED-DC52-4E28-B813-0C4F58FCC526Q38797526-28294C39-1AEF-4AEA-86EB-62313F8EE04AQ39982450-953A2A73-190F-4DA2-96DF-77FC3B72D408Q40765943-43EBC682-368D-46E2-A946-F09C5C14EE22Q41557136-0C3093CF-6D88-4D55-8755-1B91B9BE75ADQ41876225-4CC5EFF5-407E-4EBF-8059-702B37A03102Q41908804-4DA75765-C745-4801-AD96-550AAA5C4AC6
P2860
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Induction of JNK and c-Abl sig ...... roficient and -deficient cells
@ast
Induction of JNK and c-Abl sig ...... roficient and -deficient cells
@en
type
label
Induction of JNK and c-Abl sig ...... roficient and -deficient cells
@ast
Induction of JNK and c-Abl sig ...... roficient and -deficient cells
@en
prefLabel
Induction of JNK and c-Abl sig ...... roficient and -deficient cells
@ast
Induction of JNK and c-Abl sig ...... roficient and -deficient cells
@en
P2093
P2860
P356
P1476
Induction of JNK and c-Abl sig ...... roficient and -deficient cells
@en
P2093
R Baskaran
R D Christen
S B Howell
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690176
P407
P577
1999-03-01T00:00:00Z